Cayman Chemical社、Genedata Screenerを導入：
Genedata Screener drives new epigenetic business for Contract Research Organization
June 28, 2011
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced Genedata Screener has been adopted by Cayman Chemical Company as the screening data-management platform for Cayman’s new Epigenetic Screening Laboratory. Cayman is a global provider of biochemical reagents, assay kits, enzymes, and antibodies. Genedata Screener, which captures and analyzes all types of screening data on a single platform, will be used by Cayman to identify epigenetic screening hits, support hit-to-lead services, and sustain lead discovery and development. Used by leading pharmaceutical companies and research organizations for both medium and high throughput screening, Genedata Screener is recognized as the fastest hit-to-lead screening analysis platform. Genedata Screener will be demonstrated at the European Lab Automation 2011 exhibition in Hamburg, Germany, June 30–July 1 (Booth # 33).
“Epigenetic research is gaining traction in both small and large pharmaceutical companies, and it will fuel a surge of therapeutic applications,” noted Dr. Jeff Johnson, vice president of Biochemistry at Cayman. “Genedata Screener enables us to get ahead of the epigenetic research curve. It gives us a proven and cost-effective screening data-management platform, which is compatible with leading screening instruments and is continually evolving with innovative technology.” As the core software system at Cayman’s Epigenetic Screening Lab, Genedata Screener will allow Cayman to capitalize on its strengths in protein production, assay development, chemical synthesis, and medicinal chemistry.
Trusted Brand for Lead Discovery
With a rich suite of enzymes and proteins not widely available, the Cayman Epigenetic Screening Lab will use Genedata Screener for small- and medium-scale throughput screening. “While Genedata Screener is known as a powerhouse in high throughput and high content screening, as well as label-free analysis, it is of course also capable of handling small- and medium-scale experiments of 10,000 to 20,000 compounds,” continued Johnson. “Combining extremely fast data processing with a high degree of flexibility, which extends to easy integration with our IT infrastructure, was a big selling point for us. Screener can support our screening business today and drive future growth.”
Initially, Cayman will use Genedata Screener to analyze results from compounds arrayed in 96- and 384-well formats at a rate of up to 100,000 compounds per week. Screening-specific business logic and capabilities for automated result calculations and comprehensive analysis workflows will reduce experiment cycles and optimize quality to accelerate Cayman’s lead discovery. “Genedata Screener’s comprehensive functionality and superior performance have created a well-known and trusted brand,” noted Johnson. “Genedata Screener as the new cornerstone of our epigenetics screening validates the quality of experiment results that we can offer our customers, ranging from small or early-stage pharmaceutical companies who don’t have screening capabilities to large pharmas looking to create efficiencies by partnering with Cayman.”
“We are excited about our collaboration with Cayman, the leader in designing and preparing novel epigenetic assays and compound libraries for human and veterinary healthcare research,” said Dr. Othmar Pfannes, CEO of Genedata. “While Cayman’s new Epigenetic Screening facility illustrates how Genedata solutions enable innovative research in drug discovery, it is especially gratifying to have Genedata Screener adopted by Cayman as a strategic business tool.”